Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy

Overview of attention for article published in The Journal of Allergy and Clinical Immunology: In Practice, June 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter: 3 X users
patent: 2 patents

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 64 Dimensions

Readers on

mendeley: 86 Mendeley

Summary X Patents Wikipedia Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 9,359 followers.

RT @FlorinDanPopesc: @IgECPD Thank you David for the revealing the Mee too approach in omalizumab dosing for chronic urticaria :) Omalizuma…

22 Apr 2018

Reply Repost Favourite

@IgECPD Thank you David for the revealing the Mee too approach in omalizumab dosing for chronic urticaria :) Omalizumab 300 mg is safe & effective in reducing CIU/CSU symptoms regardless of background therapy https://t.co/LNti5jW9RW

21 Apr 2018

Reply Repost Favourite

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy. https://t.co/Bopm1AVPhY

25 Jul 2016

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.